NCT04734678View on ClinicalTrials.gov

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

CompletedOBSERVATIONAL

Enrollment

153

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

August 1, 2021

Conditions

Covid19Cytokine StormCorona Virus Infection

Interventions

DRUG

Tocilizumab

400 mg IV only once

DRUG

Infliximab

5 mg/kg/day IV for 2 doses 12-24 hours

Trial Locations (1)

11314

Teachers Hospital, Cairo

All Listed Sponsors

collaborator

Misr International University

OTHER

lead

Ain Shams University

OTHER

NCT04734678 - Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome | Biotech Hunter | Biotech Hunter